サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1388042

がんバイオマーカーの世界市場：シェア、規模、動向、産業分析 - タイプ別、生体分子別、用途別、セグメント別予測、2023～2032年

Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
がんバイオマーカーの世界市場：シェア、規模、動向、産業分析 - タイプ別、生体分子別、用途別、セグメント別予測、2023～2032年
出版日: 2023年09月23日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんバイオマーカーの市場規模は、2032年までに533億6,000万米ドルに達すると予測されています。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

新規のがんバイオマーカーを標的とする薬剤開発への取り組みや投資の増加は、がんバイオマーカー市場の成長性を促進する上で重要な役割を果たしています。これらのバイオマーカーは、がん細胞の特定の特徴を示す指標として機能し、より的を絞った効果的な治療法の開発を可能にします。これらのユニークなバイオマーカーに注目することで、製薬会社はがんの特定のサブタイプに合わせた薬剤を開発することができ、治療成績の向上と副作用の軽減につながります。

さらに、技術的に進歩したコンパニオン診断キットのイントロダクションは、標的治療の開発を補完するものです。これらの診断キットは、患者の特定のバイオマーカーの存在を同定するのに役立ち、ヘルスケア専門家が個々の患者のプロファイルに基づいて治療計画を個別化することを可能にします。これらの診断キットによって導かれる個別化医療は、患者が最適な治療を受けられることを保証し、より良い治療反応と患者全体の転帰の向上につながります。

また、新規のがん診断技術の進歩を目的とした政府の支援イニシアティブの存在も成長を促進しています。例えば、米国国立がん研究所（NCI）は、特にがんバイオマーカーの開発に焦点を当てた8つ以上の研究分野に資金を割り当てています。Cancer Research UK、Lung Cancer Research Foundation、National Institutes of Healthといった他の組織も、バイオマーカーを中心とした研究プロジェクトに資金を提供することで重要な役割を果たしています。これらのイニシアチブは、この分野の革新と研究を促進し、新しいがん診断技術の進歩を加速しています。

アルコール摂取量が多く、タバコを使用し、不健康な食生活を送り、座りっぱなしの生活をしている人は、健康的な生活習慣を持つ人に比べ、がんを発症する可能性が80％高いことが分かっています。さらに、ヒトパピローマウイルス（HPV）、エプスタイン・バーウイルス、B型肝炎ウイルス、ヘリコバクター・ピロリ菌などの特定の感染症も、がん発症との関連の可能性について研究されています。

がんバイオマーカー市場のレポートハイライト

乳がん症例の増加、バイオマーカーに関する広範な調査、主要製品の上市により、乳がんが最大シェアを獲得

遺伝子疾患患者の増加、関連する疾患シナリオにより遺伝子バイオマーカーが急成長

個別化医療は、個別化治療オプションの最近の進歩により、急速なペースで成長すると思われます。

北米は、消費者の認知度、熟練した外科医の存在、より良いヘルスケア・インフラにより、2022年に市場で最大のシェアを占めました。

主なプレーヤーは、Abbott Laboratories、Thermo Fisher Scientific、Affymetrix、Illumina、Agilent Technologies、Merck、Hologic、Roche、QIAGEN、Sino Biological、Bectonなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のがんバイオマーカー市場に関する洞察

  • がんバイオマーカー市場 - 生体分子のスナップショット
  • がんバイオマーカー市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • PESTEL分析
  • がんバイオマーカー市場の生体分子動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のがんバイオマーカー市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • 乳がん
  • 前立腺がん
  • 大腸がん
  • 子宮頸がん
  • 肝臓がん
  • 肺がん
  • その他

第6章 世界のがんバイオマーカー市場、用途別

  • 主な調査結果
  • イントロダクション
  • 創薬・開発
  • 診断
  • 個別化医療
  • その他

第7章 世界のがんバイオマーカー市場、生体分子別

  • 主な調査結果
  • イントロダクション
  • 遺伝的バイオマーカー
  • エピジェネティックバイオマーカー
  • メタボリックバイオマーカー
  • プロテオミクスバイオマーカー
  • その他

第8章 世界のがんバイオマーカー市場、地域別

  • 主な調査結果
  • イントロダクション
    • がんバイオマーカー市場評価、地域別、2019～2032年
  • がんバイオマーカー市場 - 北米
    • 北米：がんバイオマーカー市場、タイプ別、2019～2032年
    • 北米：がんバイオマーカー市場、生体分子別、2019～2032年
    • 北米：がんバイオマーカー市場、用途別、2019～2032年
    • がんバイオマーカー市場 - 米国
    • がんバイオマーカー市場 - カナダ
  • がんバイオマーカー市場 - 欧州
    • 欧州：がんバイオマーカー市場、タイプ別、2019～2032年
    • 欧州：がんバイオマーカー市場、生体分子別、2019～2032年
    • 欧州：がんバイオマーカー市場、用途別、2019～2032年
    • がんバイオマーカー市場 - 英国
    • がんバイオマーカー市場 - フランス
    • がんバイオマーカー市場 - ドイツ
    • がんバイオマーカー市場 - イタリア
    • がんバイオマーカー市場 - スペイン
    • がんバイオマーカー市場 - オランダ
    • がんバイオマーカー市場 - ロシア
  • がんバイオマーカー市場 - アジア太平洋
    • アジア太平洋：がんバイオマーカー市場、タイプ別、2019～2032年
    • アジア太平洋：がんバイオマーカー市場、生体分子別、2019～2032年
    • アジア太平洋：がんバイオマーカー市場、用途別、2019～2032年
    • がんバイオマーカー市場 - 中国
    • がんバイオマーカー市場 - インド
    • がんバイオマーカー市場 - マレーシア
    • がんバイオマーカー市場 - 日本
    • がんバイオマーカー市場 - インドネシア
    • がんバイオマーカー市場 - 韓国
  • がんバイオマーカー市場 - 中東・アフリカ
    • 中東・アフリカ：がんバイオマーカー市場、タイプ別、2019～2032年
    • 中東・アフリカ：がんバイオマーカー市場、生体分子別、2019～2032年
    • 中東・アフリカ：がんバイオマーカー市場、用途別、2019～2032年
    • がんバイオマーカー市場 - サウジアラビア
    • がんバイオマーカー市場 - アラブ首長国連邦
    • がんバイオマーカー市場 - イスラエル
    • がんバイオマーカー市場 - 南アフリカ
  • がんバイオマーカー市場 - ラテンアメリカ
    • ラテンアメリカ：がんバイオマーカー市場、タイプ別、2019～2032年
    • ラテンアメリカ：がんバイオマーカー市場、生体分子別、2019～2032年
    • ラテンアメリカ：がんバイオマーカー市場、用途別、2019～2032年
    • がんバイオマーカー市場 - メキシコ
    • がんバイオマーカー市場 - ブラジル
    • がんバイオマーカー市場 - アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Abbott Laboratories
  • Agilent Technologies
  • Affymetrix
  • Becton
  • Hologic
  • Illumina
  • Merck
  • QIAGEN
  • Roche
  • Sino Biological
  • Thermo Fisher Scientific
図表

List of Tables

  • Table 1 Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 4 Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Cancer Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Cancer Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Biomolecule
  • Figure 11. Global Cancer Biomarkers Market, by Biomolecule, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Biomarkers Market
目次
Product Code: PM3738

The global cancer biomarkers market size is expected to reach USD 53.36 billion by 2032, according to a new study by Polaris market research. The report "Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing initiatives and investments in the development of drugs that target novel cancer biomarkers play a crucial role in driving the growth potential of the cancer biomarkers market. These biomarkers serve as indicators of specific characteristics of cancer cells, enabling the development of more targeted and effective treatments. By focusing on these unique biomarkers, pharmaceutical companies can create drugs tailored to specific subtypes of cancer, leading to improved treatment outcomes and reduced side effects.

Moreover, the introduction of technologically advanced companion diagnostic kits complements the development of targeted therapies. These diagnostic kits help identify the presence of specific biomarkers in patients, allowing healthcare professionals to personalize treatment plans based on individual patient profiles. Personalized medicine, guided by these diagnostic kits, ensures that patients receive the most suitable treatments, leading to better treatment responses and enhanced overall patient outcomes.

Growth is also facilitated by the existence of supportive government initiatives aimed at advancing novel cancer diagnostic techniques. For instance, the National Cancer Institute (NCI) allocates funding to over 8 research areas specifically focused on the development of cancer biomarkers. Other organizations such as Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health also play a significant role by providing funding for research projects centered around biomarkers. These initiatives foster innovation and research in the field, accelerating the progress of new and improved cancer diagnostic techniques.

Individuals who engage in high alcohol consumption, use tobacco, have unhealthy dietary habits, and lead a sedentary lifestyle are found to be 80% more susceptible to developing cancer compared to those with healthier habits. Additionally, certain infections, including Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori, have also been under study for their potential association with cancer development.

Cancer Biomarkers Market Report Highlights

Breast cancer held the largest share, owing to the rising cases of breast cancer, extensive research on biomarkers, & key product launches

Genetic biomarkers will grow at the rapid pace, because of rising cases of genetic disorders, and relevant diseased scenario

Personalized medicine will grow at rapid pace, owing recent advancements in personalized treatment options

North America held the largest share of the market in 2022, owing to consumer awareness, presence of skilled surgeons with better healthcare infrastructure

Key players include Abbott Laboratories, Thermo Fisher Scientific, Affymetrix, Illumina, Agilent Technologies, Merck, Hologic, Roche, QIAGEN, Sino Biological, & Becton

Polaris market research has segmented the cancer biomarkers market report based on type, biomolecule, application, and region:

Cancer Biomarkers, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Breast cancer
  • Prostate cancer
  • Colorectal cancer
  • Cervical cancer
  • Liver cancer
  • Lung cancer
  • Others

Cancer Biomarkers, Biomolecule Outlook (Revenue - USD Billion, 2023 - 2032)

  • Genetic Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers
  • Proteomic Biomarkers
  • Others

Cancer Biomarkers, Application Outlook (Revenue - USD Billion, 2023 - 2032)

  • Drug discovery and Development
  • Diagnostics
  • Personalized medicine
  • Others

Cancer Biomarkers, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Biomarkers Market Insights

  • 4.1. Cancer Biomarkers Market - Biomolecule Snapshot
  • 4.2. Cancer Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing awareness among patients and healthcare professionals about the importance of early diagnosis of malignancies.
      • 4.2.1.2. Rising demand for personalized medicine
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High capital investment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Cancer Biomarkers Market Biomolecule Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cancer Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Breast cancer
    • 5.3.1. Global Cancer Biomarkers Market, by Breast cancer, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostate cancer
    • 5.4.1. Global Cancer Biomarkers Market, by Prostate cancer, by Region, 2019-2032 (USD Billion)
  • 5.5. Colorectal cancer
    • 5.5.1. Global Cancer Biomarkers Market, by Colorectal cancer, by Region, 2019-2032 (USD Billion)
  • 5.6. Cervical cancer
    • 5.6.1. Global Cancer Biomarkers Market, by Cervical cancer, by Region, 2019-2032 (USD Billion)
  • 5.7. Liver cancer
    • 5.7.1. Global Cancer Biomarkers Market, by Liver cancer, by Region, 2019-2032 (USD Billion)
  • 5.8. Lung cancer
    • 5.8.1. Global Cancer Biomarkers Market, by Lung cancer, by Region, 2019-2032 (USD Billion)
  • 5.9. Others
    • 5.9.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Cancer Biomarkers Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Drug discovery and Development
    • 6.3.1. Global Cancer Biomarkers Market, by Drug discovery and Development, by Region, 2019-2032 (USD Billion)
  • 6.4. Diagnostics
    • 6.4.1. Global Cancer Biomarkers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
  • 6.5. Personalized medicine
    • 6.5.1. Global Cancer Biomarkers Market, by Personalized medicine, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Cancer Biomarkers Market, by Biomolecule

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
  • 7.3. Genetic Biomarkers
    • 7.3.1. Global Cancer Biomarkers Market, by Genetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.4. Epigenetic Biomarkers
    • 7.4.1. Global Cancer Biomarkers Market, by Epigenetic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.5. Metabolic Biomarkers
    • 7.5.1. Global Cancer Biomarkers Market, by Metabolic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.6. Proteomic Biomarkers
    • 7.6.1. Global Cancer Biomarkers Market, by Proteomic Biomarkers, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Cancer Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Cancer Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Biomarkers Market - North America
    • 8.3.1. North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Biomarkers Market - Canada
      • 8.3.5.1. Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Cancer Biomarkers Market - Europe
    • 8.4.1. Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Biomarkers Market - UK
      • 8.4.4.1. UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Biomarkers Market - France
      • 8.4.5.1. France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Biomarkers Market - Germany
      • 8.4.6.1. Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Biomarkers Market - Italy
      • 8.4.7.1. Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Biomarkers Market - Spain
      • 8.4.8.1. Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Biomarkers Market - Russia
      • 8.4.10.1. Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Cancer Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Biomarkers Market - China
      • 8.5.4.1. China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Biomarkers Market - India
      • 8.5.5.1. India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Biomarkers Market - Japan
      • 8.5.7.1. Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Cancer Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Biomarkers Market - UAE
      • 8.6.5.1. UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Biomarkers Market - Israel
      • 8.6.6.1. Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Cancer Biomarkers Market - Latin America
    • 8.7.1. Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Agilent Technologies
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Affymetrix
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Becton
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Hologic
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Illumina
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. QIAGEN
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sino Biological
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Thermo Fisher Scientific
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development